$ News

Novo Integrated Sciences Reports 2024 Fiscal Year Financial Results

Novo Integrated Sciences Ends $60M Gemstone Deal

Novo Integrated Sciences GAAP EPS of -$0.74, revenue of $3.15M

Novo Integrated Sciences Reports Fiscal Year 2024 Third Quarter Financial Results

NVOS Stock Earnings: Novo Integrated Sciences Reported Results for Q3 2024

Novo Integrated Sciences Receives Commencement of Disbursement Notice for SBLC Leasing and Monetizing Program

Novo Integrated Sciences Announces Major Funds Disbursement

Novo Integrated Sciences: A Coil Spring Ready To Explode

Novo Integrated Sciences Secures Leadership Until 2025

Novo Integrated Sciences Receives Confirmation of Issuance of SBLC by HSBC for SBLC Leasing and Monetizing Program

Novo Integrated Sciences Secures $78 Million Funding via HSBC

Novo Integrated Sciences’ Board of Directors Approves Increase of Maximum Amount Under Stock Repurchase Program to $10 Million

Novo Integrated Sciences Doubles Stock Buyback Program

Novo Integrated board boosts maximum amount under stock buyback to $10M

Acenzia Selected to Participate in Protein Industries Canada Program to Develop Plant Based Protein Products

Novo Integrated Sciences Ventures into Global Protein Market

Novo Integrated Sciences and RC Consulting Consortium Group Amend $70,000,000 Promissory Note

Novo Integrated Sciences Amends Promissory Note Terms

Day Trading During A Slow Holiday Week

Novo Integrated Sciences’ Board of Directors Conducting Strategic Review to Increase Maximum Amount under Stock Repurchase Program